Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

• Status: Completed
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is being conducted to see if the investigational medication, valopicitabine, is safe to use in combination with ribavirin, a drug approved by the FDA for treating hepatitis C infection.

• Phase: Phase 2

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Collaborator: Novartis Pharmaceuticals
• Treatments: Peginterferon alfa-2a; Ribavirin

Criteria

Inclusion Criteria:

• Documented clinical history compatible with chronic hepatitis C and compensated liver disease

• Has not previously received anti-viral therapy for hepatitis C infection

Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Patient is pregnant or breastfeeding

• Patient is co-infected with hepatitis B virus and/or HIV

Other protocol-defined exclusion criteria may apply.